Investor News View all

Doseology Completes Development and Test Marketing of Adaptogenic Mushroom Product Line
Investor Year End Update
Doseology Prepares to Expand Mushroom Production by Hiring Dr. Wellman-Labadie to Oversee Planned Research and Development Laboratory
Doseology Prepares for Growth Phase in Psychedelic-Focused Mental Health Market, Completes Dealer’s License Application
Doseology Set to Trade CSE: MOOD
Doseology Receives Receipt for Final Prospectus and Amounts Listing on the CSE : MOOD
Doseology Receives Receipt for Final Prospectus and Announces Listing on the CSE
Doseology Raises $4,451,568 and Files Preliminary Non-offering Prospectus.